Unknown

Dataset Information

0

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy.

ABSTRACT:

SUBMITTER: Abbas HA 

PROVIDER: S-EPMC9996355 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy.
| S-EPMC9647734 | biostudies-literature
Unknown Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
| S-EPMC7218423 | biostudies-literature
Unknown The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy.
| S-EPMC11833631 | biostudies-literature
Unknown Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
| S-EPMC12510377 | biostudies-literature
Unknown Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
| S-EPMC9631686 | biostudies-literature
Unknown Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML.
| S-EPMC12356277 | biostudies-literature
Unknown Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
| S-EPMC11652759 | biostudies-literature
Unknown Improving long-term outcomes with intensive induction chemotherapy for patients with AML.
| S-EPMC10727094 | biostudies-literature
Unknown Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
| S-EPMC8528825 | biostudies-literature
Unknown Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively.
| S-EPMC9771201 | biostudies-literature